A monoclonal antibody against PMEL

Area of Science:

• Biochemistry
• Immunology
• Dermatology

Background:

• PMEL (preliminary melanoma antigen), also known as Pmel17 or gp100, is a melanocyte-specific glycoprotein vital for melanosome formation.
• Its restricted expression and transient cell surface presence make PMEL a potential target for antibody drug conjugate (ADC) therapy in pigmentary diseases.

Purpose of the Study:

• To generate high-specificity and high-affinity monoclonal antibodies (mAbs) against human PMEL for ADC therapy research.
• To characterize and validate the specificity and binding capabilities of newly developed anti-PMEL mAbs.

Main Methods:

• Immunization of BALB/c mice with recombinant PMEL-GST fusion protein to produce mAbs.
• Characterization of mAbs using immunoglobulin subclass assay, Western blotting, immunohistochemistry, and flow cytometry.

Main Results:

• Three anti-PMEL mAbs (A3F, G11B, J7E) were successfully generated with high titers.
• Specificity analysis revealed that G11B reacted exclusively with PMEL, while A3F and J7E showed cross-reactivity.
• G11B demonstrated specific binding to human PMEL in normal skin and on PMEL-positive melanoma cells via immunohistochemistry and flow cytometry.

Conclusions:

• The monoclonal antibody G11B exhibits high specificity for the PMEL antigen.
• G11B serves as a valuable tool for further research and development of antibody drug conjugate therapies targeting pigmentary diseases.